Objective Coronavirus disease 2019 (COVID-19) represents a novel pneumonia leading to
severe acute respiratory syndrome (SARS). Recent studies documented that SARS-…

β 2 -Agonists are effective bronchodilators due primarily to their ability to relax airway
smooth muscle (ASM). They exert their effects via their binding to the active site of β 2 -…

BACKGROUND: General anesthesia with single-lung ventilation is considered mandatory for
thoracoscopic pulmonary resection. We assessed in a randomized study the feasibility and …

The natural history of idiopathic pulmonary fibrosis (IPF) is not well defined and its clinical
course is variable. We sought to investigate the survival and incidence of acute exacerbations (…

Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with
chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out …

With the aim to individuate alleles that may reflect a higher susceptibility to the disease, in
the present study we analyzed the HLA allele frequency distribution in a group of 99 Italian …

Background Inhaled medication is the cornerstone of the pharmacological treatment for
patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler …

Objectives In airway infections, biofilm formation has been demonstrated to be responsible
for both acute and chronic events, and constitutes a genuine challenge in clinical practice. …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …